Tempus Expands Immuno-Oncology Portfolio With The Launch Of AI-Enabled, Multimodal Immune Profile Algorithmic Tests For Research Use Only

7/16/24 9:33:15 AM ET

Computer Software: Programming Data Processing

Technology

Get the next $TEM alert in real time by email

Available Today for Life Science Research Use Only

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, to bring additional immunotherapy-focused algorithmic tests to this growing portfolio, leveraging clinical, laboratory, genomic, and transcriptomic data to identify patients that may respond to immunotherapy.

Get the next $TEM alert in real time by email

Date	Price Target	Rating	Analyst
11/11/2024	$45.00 → $65.00	Buy → Hold	Stifel
10/2/2024	$45.00 → $60.00	Buy → Neutral	BofA Securities
8/12/2024	$40.00	Neutral	Piper Sandler
7/9/2024	$41.00	Buy	BofA Securities
7/9/2024	$45.00	Buy	Stifel
7/9/2024	$42.00	Overweight	JP Morgan
7/9/2024	$44.00	Overweight	Morgan Stanley
7/9/2024	$48.00	Buy	Longbow

Tempus Expands Immuno-Oncology Portfolio With The Launch Of AI-Enabled, Multimodal Immune Profile Algorithmic Tests For Research Use Only

Chat with this insight

Recent Analyst Ratings for
$TEM

$TEM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Accounting Officer Bartolucci Ryan M was granted 10,000 shares, increasing direct ownership by 16% to 71,346 units (SEC Form 4)

Chief Financial Officer Rogers James William was granted 30,000 shares, increasing direct ownership by 11% to 314,305 units (SEC Form 4)

EVP and General Counsel Polovin Andrew was granted 30,000 shares, increasing direct ownership by 11% to 297,589 units (SEC Form 4)

$TEM
Financials

Live finance-specific insights

Tempus to Report Third Quarter 2024 Financial Results on November 4

Tempus to Report Third Quarter 2024 Financial Results on November 7

Tempus to Report Second Quarter 2024 Financial Results on August 6

$TEM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Tempus AI Inc.

SEC Form SC 13G filed by Tempus AI Inc.

Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

$TEM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

$TEM
SEC Filings

$TEM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Tempus AI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

SEC Form SCHEDULE 13G filed by Tempus AI Inc.

SEC Form 10-Q filed by Tempus AI Inc.

Tempus AI downgraded by Stifel with a new price target

Tempus AI downgraded by BofA Securities with a new price target

Piper Sandler initiated coverage on Tempus AI with a new price target

$TEM
Press Releases

Fastest customizable press release news feed in the world

Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

$TEM
Market Insights

Live Market Insights

Riot Platforms & North Face Parent V.F. Corp Are Among 11 Mid-Cap Stocks That Performed The Best Last Week (July 14-July 20): Are Others In Your Portfolio?

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday